OncoMed racks up three straight clinical disasters as lead drug implodes
OncoMed $OMED just added a fresh page to its nightmare story on cancer drug development.
Following up recent back-to-back clinical failures, the biotech says that its lead drug — demcizumab, partnered with Celgene — just failed a Phase II study for non-small cell lung cancer. The drug already failed a Phase II study for pancreatic cancer recently. And then three weeks ago tarextumab plus chemo also failed a Phase II study. And that all followed a key mid-stage flop a year ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.